Lindsay E A, Berenbaum M C, Bonnett R, Thomas D G
Department of Experimental Pathology, St Mary's Hospital Medical School, London, UK.
Br J Cancer. 1991 Feb;63(2):242-6. doi: 10.1038/bjc.1991.57.
Subcutaneous and intracranial VMDk tumours were treated with photodynamic therapy (PDT) using a new sensitiser, m-THPP. Subcutaneous tumours were highly sensitive to PDT but intracranial tumours were much more resistant, requiring a 30-fold increase in sensitiser dose to produce equivalent levels of necrosis. Resistance of intracerebral tumours was not due to failure of the sensitiser to enter tumours. Necrosis of intracranial tumours was increased when mice breathed 100% oxygen during PDT while subcutaneous tumour necrosis was unaffected.
皮下和颅内VMDk肿瘤采用新型敏化剂m-THPP进行光动力疗法（PDT）治疗。皮下肿瘤对PDT高度敏感，但颅内肿瘤的耐药性要强得多，需要将敏化剂剂量增加30倍才能产生同等程度的坏死。脑内肿瘤的耐药性并非由于敏化剂未能进入肿瘤。在PDT期间让小鼠呼吸100%氧气时，颅内肿瘤的坏死增加，而皮下肿瘤的坏死不受影响。
